BE COOL PHARMACEUTICS LLC — Department of Health and Human Services STTR Phase I: NHLBI
BE COOL PHARMACEUTICS LLC — STTR Phase I award from Department of Health and Human Services.
Phase I STTR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $457,306. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code NHLBI links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $457,306
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- STTR · Phase I
- Topic
- NHLBI
- Solicitation
- PA19-029
- NAICS
- —
- Place of performance
- AK
- Period
- 2017-09-01 → 2020-08-31
Description
Summary The temperature management market is expected to reach $billion byyet no pharmaceutical has yet been developed specifically for this marketAadenosineA ARagonists are well known to attenuate seizure and protect the brain from injurybut development of these drugs has been limited by side effects including hypothermiabradycardia and hypotensionInspired by our discoveries thatN cyclohexyl adenosineCHAlowers body temperature and induces hibernation and that cardiovascular side effects of CHA can be reversed with a peripherally acting adenosine receptor antagonistp Sulfophenyl theophyllineSPTwithout affecting body temperaturethe present proposal aims to meet three milestones that will define the market to target for commercializationAimis to meet our first milestone which is to demonstrate that CHASPT attenuates shivering better than state of the art meperidine buspirone in rats cooled toCAimis to meet our second milestone which is to demonstrate CHASPTattenuates seizure better than meperidine buspirone and Aimis to meet our third milestone to demonstrate neuroprotective efficacy of CHASPT at target temperatures ofC andC while showing that CHASPT controls shivering and seizure at both target temperaturesWhen completed we will have necessary preliminary data to define the thermolyticantiseizure and neuroprotective efficacy and side effects of CHASPT relative to the state of the art antishivering medicationThese outcomes will be accomplished through standard methods currently used in the PIandapos s laboratoryThe results will significantly contribute to proving the scientific and technical feasibility of developing CHA combined withSPT as a novel thermolytic and antiseizure medication that will make targeted temperature management accessible to underserved populations and meet market demand to treat post operative shiveringThe proposed work is necessary to justify additional support in Phase II Narrative Post operative shivering is driving market demand for effective anti shivering agentsWe will develop a drug toInhibit shivering andMake targeted temperature management accessible to underserved cardiac arrest patients living in rural and remote locations